Current Ratio
31.85x
Period-end balance · Through 30 Sep 2023
RayzeBio, Inc. financial metrics
Period Q3 2023 · Filed 13 Nov 2023
Key metrics snapshot
NetIncomeLoss YoY
11%
Quarter · Through 30 Sep 2023
Financial Health
| Metric | Latest value | YoY relative change |
|---|---|---|
| Current Ratio |
31.85x
Period-end balance · 30 Sep 2023
|
Growth
| Metric | Latest value | YoY relative change |
|---|---|---|
| NetIncomeLoss YoY |
11%
Quarter · 30 Sep 2023
|
Share Metrics
| Metric | Latest value | YoY relative change |
|---|---|---|
| Entity Common Stock, Shares Outstanding |
59,919,502
Period-end balance · 07 Nov 2023
|
|
| Common Stock, Shares, Outstanding |
59,826,184
Period-end balance · 30 Sep 2023
|
|
| Common Stock, Value, Issued |
$6,000
Period-end balance · 30 Sep 2023
|
|
| Weighted Average Number of Shares Outstanding, Basic |
15,399,901
Reported period · 30 Sep 2023
|
+303% |
| Weighted Average Number of Shares Outstanding, Diluted |
15,399,901
Reported period · 30 Sep 2023
|
+303% |
Supporting Metrics
These supporting metrics stay fully source-backed for deeper research. Scan the latest value and reported period first, then open a metric page when you need the full filing trail.
| Metric | Latest value | YoY relative change |
|---|---|---|
| Accounts Payable, Current |
$2,237,000
Period-end balance · 30 Sep 2023
|
|
| Accrued Liabilities, Current |
$13,610,000
Period-end balance · 30 Sep 2023
|
|
| Accumulated Other Comprehensive Income (Loss), Net of Tax |
-$386,000
Period-end balance · 30 Sep 2023
|
|
| Additional Paid in Capital |
$755,829,000
Period-end balance · 30 Sep 2023
|
|
| Assets |
$603,513,000
Period-end balance · 30 Sep 2023
|
|
| Assets, Current |
$544,986,000
Period-end balance · 30 Sep 2023
|
|
| Cash and Cash Equivalents, at Carrying Value |
$251,964,000
Period-end balance · 30 Sep 2023
|
+17% |
| Cash, Cash Equivalents, and Short-term Investments |
$540,200,000
Period-end balance · 30 Sep 2023
|
|
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
$252,303,000
Period-end balance · 30 Sep 2023
|
+17% |
| Common Stock, Par or Stated Value Per Share |
0
Period-end balance · 30 Sep 2023
|
|
| Common Stock, Shares Authorized |
700,000,000
Period-end balance · 30 Sep 2023
|
|
| Common Stock, Shares, Issued |
61,047,189
Period-end balance · 30 Sep 2023
|
|
| Comprehensive Income (Loss), Net of Tax, Attributable to Parent |
-$19,220,000
Reported period · 30 Sep 2023
|
+23% |
| Depreciation |
$500,000
Reported period · 30 Sep 2023
|
+25% |
| Earnings Per Share, Basic |
-1.26
Reported period · 30 Sep 2023
|
+81% |
| Earnings Per Share, Diluted |
-1.26
Reported period · 30 Sep 2023
|
+81% |
| Employee-related Liabilities, Current |
$3,076,000
Period-end balance · 30 Sep 2023
|
|
| General and Administrative Expense |
$3,481,000
Reported period · 30 Sep 2023
|
+64% |
| Lessee, Operating Lease, Liability, to be Paid |
$12,579,000
Period-end balance · 30 Sep 2023
|
|
| Lessee, Operating Lease, Liability, to be Paid, Year Four |
$2,261,000
Period-end balance · 30 Sep 2023
|
|
| Lessee, Operating Lease, Liability, to be Paid, Year One |
$2,070,000
Period-end balance · 30 Sep 2023
|
|
| Lessee, Operating Lease, Liability, to be Paid, Year Three |
$2,196,000
Period-end balance · 30 Sep 2023
|
|
| Lessee, Operating Lease, Liability, to be Paid, Year Two |
$2,132,000
Period-end balance · 30 Sep 2023
|
|
| Lessee, Operating Lease, Liability, Undiscounted Excess Amount |
$2,855,000
Period-end balance · 30 Sep 2023
|
|
| Liabilities and Equity |
$603,513,000
Period-end balance · 30 Sep 2023
|
|
| Liabilities, Current |
$17,113,000
Period-end balance · 30 Sep 2023
|
|
| Operating Income (Loss) |
-$21,651,000
Reported period · 30 Sep 2023
|
-3.3% |
| Operating Lease, Liability |
$9,724,000
Period-end balance · 30 Sep 2023
|
|
| Operating Lease, Liability, Current |
$1,266,000
Period-end balance · 30 Sep 2023
|
|
| Operating Lease, Liability, Noncurrent |
$8,458,000
Period-end balance · 30 Sep 2023
|
|
| Operating Lease, Payments |
$501,000
Reported period · 30 Sep 2023
|
+2.9% |
| Operating Lease, Right-of-Use Asset |
$8,484,000
Period-end balance · 30 Sep 2023
|
|
| Operating Lease, Weighted Average Discount Rate, Percent |
0.09
Period-end balance · 30 Sep 2023
|
|
| Other Assets, Noncurrent |
$8,000
Period-end balance · 30 Sep 2023
|
|
| Preferred Stock, Par or Stated Value Per Share |
0
Period-end balance · 30 Sep 2023
|
|
| Preferred Stock, Shares Authorized |
10,000,000
Period-end balance · 30 Sep 2023
|
|
| Preferred Stock, Shares Issued |
0
Period-end balance · 30 Sep 2023
|
|
| Preferred Stock, Shares Outstanding |
0
Period-end balance · 30 Sep 2023
|
|
| Property, Plant and Equipment, Gross |
$52,990,000
Period-end balance · 30 Sep 2023
|
|
| Property, Plant and Equipment, Net |
$49,696,000
Period-end balance · 30 Sep 2023
|
|
| Research and Development Expense |
$18,170,000
Reported period · 30 Sep 2023
|
-3.5% |
| Retained Earnings (Accumulated Deficit) |
-$180,127,000
Period-end balance · 30 Sep 2023
|
|
| Share-based Payment Arrangement, Expense |
$2,564,000
Reported period · 30 Sep 2023
|
+77% |
| Stockholders' Equity Attributable to Parent |
$575,322,000
Period-end balance · 30 Sep 2023
|
Comparisons, sources and research notes
Sources and sharing
RayzeBio, Inc. Financial Facts
- Context
- Latest metrics period: Q3 2023
- Latest reported value
- Current Ratio 31.85x
Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Open metric pages to inspect the reported history.
Tracking and update notes
Why revisit this company facts page
Company facts change as new 10-Q and 10-K filings update the latest reported period, headline values, and cross-company comparison context.
- Latest source-backed update
- Latest metrics period Q3 2023
- Why come back
- Use the next filing cycle to compare new facts against this baseline and then verify the detailed metric history.
- Current latest metrics period: Q3 2023.
- Most recent SEC facts end date on this page: 07 Nov 2023.
- Save this filer to return when the next filing-backed metric period changes the picture.
Freshness comes from the latest SEC company facts period available for this filer and the linked metric history pages.
Latest update
Latest update for RayzeBio, Inc.
Latest financial period: Q3 2023. Reopen this facts page to verify the newest reported period against the prior baseline.
Update date
13 Nov 2023
Page type
Company facts
Latest period
Q3 2023
SEC-backed company facts were refreshed from filings filed on 13 Nov 2023.
Benchmark Context
How Current Ratio compares
Current Ratio does not yet have enough prior-period data for a historical comparison on this page.
Compared with
Compared with RayzeBio, Inc.'s recent history first. Same-industry peer context appears only when enough SEC-backed benchmark coverage exists.
Why this is notable
Current Ratio already has a self-history signal here, but same-industry benchmark context waits until the benchmark sample is strong enough.
- Latest comparable period on this page: Q3 2023.
- Peer context will appear when enough companies report a comparable value for this metric.
- Open the metric history first if you want to verify the exact period-to-period change.
Industry benchmark context uses SEC-reported values from the same methodology version. Latest periods may differ across companies.
How to read key metrics on this page
These short guides explain what the headline metrics mean, what to compare next, and where to open the live SEC-backed example for this company.
Plain-English Guide
How to read Net Income on this page
Net income is profit after operating costs, interest, taxes, and other non-operating items.
Why people care
It is the bottom-line profit figure many users recognize first, especially when they want to compare earnings with sales or cash flow.
How to read it
Use the same quarter or fiscal year comparison first, then check operating income or cash flow if the bottom line moved sharply.
Compare next
Compare it with operating income, EPS, and operating cash flow to see whether earnings are broad-based or driven by one-off items.
Net income can swing because of tax, financing, or accounting adjustments, so it is often less comparable than core operating metrics.
Open a live SEC-backed example
Filing notes and source
Key facts
- RayzeBio, Inc. financial facts use SEC filings; any third-party reference is labeled separately.
- Latest metrics period on this page: Q3 2023.
- Headline metric: Current Ratio 31.85x.
Change
- Comparable YoY change is unavailable for this metric.
- Most recent SEC facts end date: 07 Nov 2023.
Research use
- This gives a beginner-friendly first read before you inspect detailed formulas and metric tables.
- Metric cards link to SEC history; a third-party reference may use a different or unverified reporting period.
Evidence
Based on latest 10-Q/10-K
View source filing
Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Open company facts to inspect the reported metric history.
Latest financial snapshot (2023-11-07) highlights Current Ratio 31.85x and NetIncomeLoss YoY 11.0%.
Valuation Snapshot
SEC-only DCF estimate using a normalized free cash flow base, cash, debt, and reported share count when available.
No market comparison
USD inputs only. Cash and complete debt must share the latest balance date. Missing balances are unknown, never zero; equity value and market EV remain unavailable until both are verified.
DCF estimate is unavailable because required valuation inputs are missing.
Missing: Free cash flow.
Input periods, units and SEC sources
Equity value = DCF enterprise value + cash − debt. Cash flow uses matching annual or trailing-12-month periods.
- Operating cash flow: unavailable on a verified comparable basis
- Capital expenditures: unavailable on a verified comparable basis
- Cash and equivalents: 540,200,000.0 USD · through 2023-09-30 SEC source
- Debt: unavailable on a verified comparable basis
Data confidence notes
- Free cash flow unavailable: matching usd annual or trailing-12-month operating cash flow and cash capex are required
- Debt unavailable: no complete usd debt balance at the latest balance date
- Ticker missing for issuer
- Valuation unavailable: free cash flow is missing
Compare This Company Through SEC-backed Metrics
Use these links to compare RayzeBio, Inc. against other SEC filers on the same metric, then verify the company history from the paired facts page.
NetIncomeLoss YoY
Latest value: 11%
Financial Quality Score
Transparent 0-100 scoring model based on profitability, financial health, and growth factors.
35.3/100
Weak Confidence low
Financial Health
- Current Ratio
- 31.85x
Strengths
NetIncomeLoss YoY
Watchpoints
Current Ratio
Calculation methodology and other links
How we score
This score is transparent and deterministic. We weight profitability, financial health, and growth metrics, then renormalize weights when SEC data is missing.
| Metric | Weight | V1 threshold |
|---|---|---|
| ROIC | 20 | 5% to 20% |
| ROE | 15 | 8% to 25% |
| ROA | 10 | 2% to 10% |
| Operating Margin | 5 | 5% to 25% |
| Current Ratio | 12 | 1.0x to 2.0x |
| Quick Ratio | 8 | 0.8x to 1.5x |
| Debt to Equity | 10 | 0.3x to 2.0x (lower is better) |
| Revenue YoY | 10 | -10% to +20% |
| Net Income YoY | 10 | -10% to +20% |
How Calculated (standard_v1)
Metrics are computed with a market-consensus convention designed for cross-portal comparability.
- Operating Income / Revenues using matching TTM or quarter periods; basis shown per metric
- Current Assets / Current Liabilities (latest instant quarter)
- (Current Assets - Inventory) / Current Liabilities; fallback: (Cash+Short-Term Investments + Accounts Receivable) / Current Liabilities
- Total Debt / Stockholders Equity (latest instant quarter; shared unit; freshest series)
- TTM Net Income / Average Equity (current quarter + same quarter previous year) / 2
- TTM Net Income / Average Assets (current quarter + same quarter previous year) / 2
- TTM NOPAT / Average Invested Capital, where NOPAT=Operating Income*(1-tax rate), Invested Capital=Equity+Total Debt-Cash & ST Investments
- Revenues YoY using available TTM or quarter comparison; basis shown per metric
- Net Income YoY using available TTM or quarter comparison; basis shown per metric
CIK / security context first